ABBV · 10-Q · 2026Q2 · Full report
Cash Flow and Capital Allocation
AbbVie Inc. · 2026-08-03 · Importance 33 · Surprise 32 · From source text
Operating cash flow increased to $7.265 billion for the six months ended June 30, 2026 from $6.788 billion, primarily due to stronger operating results and lower litigation payments. Capital expenditures increased to $587 million from $504 million, while acquisition and investment payments totaled $1.1 billion net of cash acquired. AbbVie paid $6.2 billion in dividends and repurchased 5 million shares for $1.1 billion during the six months ended June 30, 2026. The company declared a quarterly dividend of $1.73 per share on June 18, 2026, payable August 14, 2026.
Key facts
- Cash dividend payments during the six months ended June 30, 2026: $6.2 billion; for the six months ended June 30, 2025: $5.8 billion; increase primarily due to increase in the quarterly dividend rate. source
- Operating cash flows for the six months ended June 30, 2026: $7,265 million compared to $6,788 million in prior year; investing activities cash flows: $(1,771) million vs $(1,916) million; financing activities cash flows: $(4,135) million vs $(3,968) million. source
- On June 18, 2026 AbbVie's board declared a quarterly dividend of $1.73 per share for stockholders of record at close of business on July 15, 2026, payable on August 14, 2026. source
- Cash flows from operations for the six months ended June 30, 2026: $7.3 billion. source
- AbbVie repurchased 5 million shares for $1.1 billion during the six months ended June 30, 2026 and repurchased 3 million shares for $606 million during the six months ended June 30, 2025. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | realized | -0.8% | AbbVie repurchased 5 million shares for $1.1 billion during the six months ended June 30, 2026 and repurchased 3 million shares for $606… |
| cash | positive | realized | +0.3% | Operating cash flows for the six months ended June 30, 2026: $7,265 million compared to $6,788 million in prior year; investing activities… |
| cash | negative | realized | -0.3% | Cash dividend payments during the six months ended June 30, 2026: $6.2 billion; for the six months ended June 30, 2025: $5.8 billion;… |
| cash | negative | realized | -0.1% | Operating cash flows for the six months ended June 30, 2026: $7,265 million compared to $6,788 million in prior year; investing activities… |
| cash | positive | realized | +0.1% | Operating cash flows for the six months ended June 30, 2026: $7,265 million compared to $6,788 million in prior year; investing activities… |
| liability | negative | committed | — | On June 18, 2026 AbbVie's board declared a quarterly dividend of $1.73 per share for stockholders of record at close of business on July… |
| cash | negative | committed | — | On June 18, 2026 AbbVie's board declared a quarterly dividend of $1.73 per share for stockholders of record at close of business on July… |